View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 8, 2021updated 11 Jul 2022 2:16pm

Medicago’s Covid-19 shot shows efficacy against variants in trial

The vaccine candidate had a 75.3% efficacy against Covid-19 of any severity caused by the Delta variant of SARS-CoV-2.

GlaxoSmithKline (GSK) and Medicago have reported that a plant-based Covid-19 vaccine candidate, given with an adjuvant showed an overall efficacy of 71% against all SARS-CoV-2 variants in a Phase III clinical trial.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The study evaluated Medicago’s plant-based vaccine candidate for Covid-19 in combination with the pandemic adjuvant of GSK.

Commenced in March 2021, the randomised, event-driven, crossover placebo-controlled, observer-blinded Phase III segment of a Phase II/III trial analysed the efficacy and safety of the vaccine candidate versus placebo.

It enrolled more than 24,000 participants aged 18 years and above in the US, UK, Canada, Mexico, Argentina and Brazil.

The trial subjects received two intramuscular doses of the vaccine at a gap of 21 days.

For the Delta variant of the virus, findings showed that the vaccine candidate had a 75.3% efficacy against Covid-19 of any severity.

GSK noted that the trial met the primary and secondary endpoints, and the vaccine also had an 88.6% efficacy against the Gamma variant.

No significantly serious side effects were observed in the trial with mild to moderate and temporary reactogenicity noted.

The shot was found to be well-tolerated with the safety profile in the Phase III trial in line with that reported in Phase II.

Based on the latest data, Medicago intends to obtain approval from Health Canada as part of the rolling submission.

In April, the Canadian regulatory authority accepted for review the initial portion of the rolling submission made by Medicago for its vaccine candidate.

GSK global Covid-19 adjuvanted vaccines lead and chief global health officer Thomas Breuer said: “These are encouraging results given data were obtained in an environment with no ancestral virus circulating.

“The combination of GSK’s established pandemic adjuvant with Medicago’s plant-based vaccine technology has significant potential to be an effective, refrigerator-stable option to help protect people against SARS-CoV-2.”

GSK collaborated with Medicago to develop, evaluate and produce a plant-based adjuvanted Covid-19 shot, in July 2020.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena